Cardiff Oncology Inc. (CRDF)
The price, the headline numbers and the latest news, in one place.
Cardiff Oncology Inc. (CRDF) Stock Price, Analysis & Data
| Bid | 0.69 |
| Market Cap | 73.13M |
| Revenue (ttm) | 508K |
| Net Income (ttm) | -40.08M |
| 1.44 | |
| -0.6 | |
| n/a | |
| -1.61 | |
| P/B (ttm) | 2.43 |
| P/S (ttm) | 143.95 |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.23 |
| Volume | 526,299 |
| Avg. Volume (20D) | 1,447,437 |
| Open | 0.99 |
| Previous Close | 0.99 |
| Day's Range | 0.93 - 0.99 |
| 52-Week Range | 0.76 - 3.31 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...
Financial Performance
In 2025, Cardiff Oncology's revenue was 593K, a decrease of -13.18% compared to the previous year's 683K. Earnings were -45.85M, an increase of 0.92%.
Financial StatementsEarnings Surprise
- Revenue of $41K misses estimates by $0, with -62.39% YoY decline.
- EPS of -0.14 exceeds estimates by 0.02, with 33.33% YoY growth.
Analysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
Cardiff Oncology And 2 Other Promising Penny Stocks For Your WatchlistOver the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...
